Cedars-Sinai Medical Center

medical staff pulse newsletter

Text size: A A A
A BI-WEEKLY PUBLICATION FROM THE CEDARS-SINAI CHIEF OF STAFF April 8, 2016 | Archived Issues

Recognition for Danoff, Murrell and Noah

Physician News

Dudley Danoff, MD, discussed his new book before a large crowd at the Medical Library, Zuri A. Murrell, MD, spoke to a church congregation about colorectal cancer, and Mark S. Noah, MD, will become the local governor of the American College of Physicians.

» Read more


Meetings and Events


Grand Rounds

Click here to view upcoming grand rounds.


Upcoming CME Conferences

Click below to view a complete list of all scheduled Continuing Medical Education conferences.

CME Newsletter - April 2016 (PDF)  


Milestones

Do you know of a significant event in the life of a medical staff member? Please let us know, and we'll post these milestones in Medical Staff Pulse. Also, feel free to submit comments on milestones, and we'll post the comments in the next issue. Click here to submit your milestones and comments.

Innovation Challenge Selects Finalists

And then there were six. Ten semifinalist teams pitched detailed prototypes of their innovative ideas to improve patient care at Innovation Day, the second event in the MD/RN Patient Experience Innovation Challenge, held Monday, March 28.

» Read more

Cytogenetics Lab Wins Key State Approval

The Cedars-Sinai Cytogenetics Laboratory recently became the first in California to gain approval for administering chromosomal microarray testing to women participating in the state's long-running Prenatal Screening Program. Cedars-Sinai is also among a small number of medical centers statewide that have both a lab and a prenatal diagnosis center with longstanding approvals from the Department of Public Health.

» Read more

CS-Link Tip: Releasing Records to Patients

cs-link logo

My CS-Link is an important piece of Cedars-Sinai's electronic health record and patient engagement. Patients report that a most-used feature of their portal is to review results. Learn how to release results that are not in your InBasket.

» Read more

New Type of HPV Test Available

The Cedars-Sinai Molecular Pathology Laboratory has announced the availability of the real­-time PCR cobas HPV Test from Roche Diagnostics.

» Read more

Summer Is Coming, and So Are Fireworks

Hollywood Bowl

Celebrate Independence Day at the Hollywood Bowl with fireworks and music by the legendary band Chicago. The event on Sunday, July 3, is open to Cedars-Sinai physicians and their immediate family members.

» Read more

FDA Warns About Opioids, Diabetes Medications

Pharmacy Focus

The U.S. Food and Drug Administration has issued warnings about safety issues with the entire class of opioid pain medicines and with Type 2 diabetes medicines containing saxagliptin and alogliptin.

» Read more

Innovation Challenge Selects Finalists

Innovation Day 1 480px

While Team Body Shop and the other semifinalists made their presentations, Harvey Morse Auditorium was bathed in blue light to set the mood. Team Body Shop earned a spot in the finals.

And then there were six.

Ten semifinalist teams pitched detailed prototypes of their innovative ideas to improve patient care at Innovation Day, the second event in the MD/RN Patient Experience Innovation Challenge, held Monday, March 28.

Innovation Day 3 220px

Among the executive judges were (from left) Mark Gavens, chief operating officer, Peggy Miles, MD, chief of staff, and Linda Burnes Bolton, DrPH, RN, FAAN, vice president and chief nursing officer.

The event in Harvey Morse Auditorium showcased the semifinalists' progress since they originally pitched their ideas to a panel of executive judges in November. Six teams will now go on to compete in the competition's final round.

"We are incredibly proud of all the teams and their dedication to creating innovative solutions for improving patient care," said Chris Ng, MD, who co-chairs the MD/RN Collaborative Challenge with Peachy Hain, MSN, RN, director of Medical, Surgical and Rehabilitation Nursing Services. "It has taken countless hours of hard work to get where the teams are today and we applaud them."

Each of the six teams will be sponsored by an executive judge in the final phase:

  • Team Heart Throbs: Created a MyChart app to allow tracheostomy or intubated patients to more easily communicate with staff and family members in multiple languages. The app aims to resolve frustrations or miscommunications with non-communicative patients.
  • Team Ohm Patrol: Developed a "Tree of Life" IV pole with a utility tray, phone charger dock and Apple iPad interface. The IV pole integrates personal touches with medicine and imagination to provide functionality and comfort.
  • Team Uber-ful Care: Selected a mobile triage app to provide patients with access to care within 30 minutes. The app looks to improve patient experience, quality, value and efficiency of care.
  • Team Cedars Engage: Built a mobile-based "Patient Power Platform" to strengthen patient and hospital relations. The goal is to improve communication between patients, family members and care providers while streamlining the workflow.
  • Team Body Shop: Integrated multidisciplinary physician, pharmacy and nursing teams to optimize the workflow by performing quarterly "tuneups" on inpatients in an effort to decrease readmissions due to medication-related adverse events.
  • Team Heart Menders: Created a patient-friendly tablet application that assists patients with selecting meals based on dietary needs and cultural preferences. It is designed to enhance communication between the interdisciplinary team and patients, while allowing nurses to focus on patient care.

The finalists will work with their sponsors to further develop and implement their prototypes during the final phase. A winning team will be selected on June 3 and will have its innovation implemented housewide.

Innovation Day 2 480px

Team Heart Menders' innovation landed the team a spot in the finals.

Cytogenetics Lab Wins Key State Approval

The Cedars-Sinai Cytogenetics Laboratory recently became the first in California to gain approval for administering chromosomal microarray testing to women participating in the state's long-running Prenatal Screening Program.

Chromosomal microarray (CMA) testing is a DNA-based method of genetic analysis that can catch abnormalities overlooked by traditional cytogenetic testing. Detection of alterations in the submicroscopic chromosome flags potential birth defects, developmental delays and genetic disorders.

"CMA testing is becoming the gold standard in analyzing genomic abnormalities," said Rhona Schreck, PhD, scientific director of the Cytogenetics Laboratory.

Last summer, the California Department of Public Health decided to make CMA testing available next year to women whose ultrasound results showed a potential for fetal abnormalities. Cedars-Sinai's lab has offered CMA testing to private patients since 2010. With the state approval, women participating in the Prenatal Screening Program will now be referred to Cedars-Sinai for testing.

Schreck spearheaded Cedars-Sinai's application process with assistance from Jennelle Hodge, PhD, associate director of the Cytogenetics Laboratory, and Kevin Baden, supervisor of the Cytogenetics Laboratory.

"We're one of the few labs statewide that have this capability," Schreck said. She submitted Cedars-Sinai's application on Feb. 8. Less than a month later, the Cytogenetics Laboratory received approval and certification from the California Department of Public Health.

"Drs. Schreck, Hodge and Lopategui have provided the highest-quality clinical cytogenetics service for many years," said David Engman, MD, PhD, chair of Pathology and Laboratory Medicine. He was referring to Jean Lopategui, MD, medical director of Molecular Pathology and Clinical Cytogenetics. "Being the first lab in California to receive approval to offer this leading-edge testing exemplifies their leadership in this important area."

Cedars-Sinai is also among a small number of medical centers statewide that have both a lab and a prenatal diagnosis center with longstanding approvals from the Department of Public Health. Both have been involved with the state program since its inception.

The department's Prenatal Screening Program was launched in 1986. About 400,000 women participate in the program each year, according to the latest state data.

"Unlike Cedars-Sinai, most prenatal diagnosis centers don't have an internal lab," Schreck said. "The fact that we do enables us to coordinate closely with Prenatal Diagnosis Center physicians as well as area obstetricians, and this is beneficial to patients."

CS-Link Tip: Releasing Records to Patients

A systematic search of the literature on patient portals demonstrates an increase in quality in terms of patient satisfaction and customer retention. There is emerging data on improvement in outcomes.

My CS-Link is an important piece of Cedars-Sinai's electronic health record and patient engagement. Patients report that a most-used feature of their portal is to review results.

Do you know how to release results that are not in your CS-Link™ InBasket? For example, a patient may want to view old results from before they signed onto My CS-Link. To do this, go to More Activities > Pt Services/Edu > MyCSLink Results Release. (Click the star so you never struggle to find this again).

Also, please come to a Physician Efficiency Training session. A list of the classes is available at CS-Link Central.

If you need assistance, email groupeisphysicians@cshs.org.

New Type of HPV Test Available

The Cedars-Sinai Molecular Pathology Laboratory has announced the availability of the real­-time PCR cobas HPV Test from Roche Diagnostics. The test is performed on the fully automated cobas 4800 System, for delivery of trustworthy results with a rapid turnaround time.

The cobas HPV Test individually identifies genotypes 16 and 18, the two highest­-risk human papillomavirus genotypes responsible for more than 70 percent of cervical cancer cases, while simultaneously detecting 12 other high-risk HPV genotypes (HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68).

One test, in one run, from one patient sample delivers three results:

  • HPV16: (positive/negative)
  • HPV18: (positive/negative)
  • Other HR HPV (positive/negative)

Genotype is included in the HPV high-risk screening test at no additional cost. Reflex testing for HPV types 16 and 18 is no longer required.

There will be no change to the HPV high-risk screening test ordering or cost.

If you have questions about this new method and the laboratory's internal validation studies, please call the laboratory at 310-423-5326.

Summer Is Coming, and So Are Fireworks

Celebrate Independence Day at the Hollywood Bowl with fireworks and music by the legendary band Chicago.

Also performing will be the Hollywood Bowl Orchestra.

The event on Sunday, July 3, is open to Cedars-Sinai physicians and their immediate family members. Cost is $135 per adult and $65 per child 3-11 years of age.

Parking passes also are available.

To reserve a place for either event, contact Cheryl Verne at 310-423-2681 or cheryl.verne@cshs.org.

Hollywood Bowl 2015 0208 480px

A photo from the 2015 celebration at the Hollywood Bowl

FDA Warns About Opioids, Diabetes Medications

Pharmacy Focus

The U.S. Food and Drug Administration has issued warnings about safety issues with the entire class of opioid pain medicines and with Type 2 diabetes medicines containing saxagliptin and alogliptin.

FDA: All Opioids Have Safety Issues

The U.S. Food and Drug Administration has issued a warning about safety issues with the entire class of opioid pain medicines, including potentially harmful interactions with antidepressants and migraine medications, adrenal insufficiency and decreased sex hormone levels.

The FDA is requiring changes to the labeling of all opioid medications to warn about these risks.

The FDA has more information.

FDA: Some Type 2 Diabetes Medicines May Increase Risk of Heart Failure

An FDA safety review has found that type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease.

As a result, the FDA is adding new warnings to the drug labels about this safety issue.

The FDA has more information.